Physician profile
Arvind Aggarwal
NPI 1154330090
$32,391.06
in general payments reported to CMS, 2019-2025
83 companies · $6,832 in 2025
The $6,832 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,996 · 2020: $4,023 · 2021: $5,084 · 2022: $5,246 · 2023: $2,045 · 2024: $6,166 · 2025: $6,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,332 · Consulting Fee: $4,689 · Travel and Lodging: $948 · Education: $774 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,331.99 |
| Consulting Fee | $4,688.75 |
| Travel and Lodging | $948.27 |
| Education | $774.48 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,574.09 | 2019-2025 | Talvey, Darzalex, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $3,397.09 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Genzyme Corporation | $3,061.71 | 2019-2025 | |
| Genmab U.S., INC. | $1,775.87 | 2025 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $1,623.47 | 2020-2025 | Libtayo, Lynozyfic |
| Novartis Pharmaceuticals Corporation | $1,397.38 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,248.75 | 2025 | |
| Merck Sharp & Dohme LLC | $1,176.42 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Athenex Pharmaceutical Division, LLC | $1,042.39 | 2019-2020 | |
| Pfizer INC. | $772.74 | 2019-2025 | |
| Daiichi Sankyo INC. | $766.98 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Alexion Pharmaceuticals, INC. | $718.91 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $693.75 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Amgen INC. | $686.23 | 2019-2023 | Lumakras |
| Seagen INC. | $662.96 | 2020-2023 | Padcev, Adcetris |
Show all 82 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.